China has emerged as a global leader in CAR-T cell therapy delivery and clinical research. Here is the current state — approved indications, leading centres, costs, and the realistic outcomes data.
China has more than 250 active CAR-T clinical trials registered (more than any other country) and three NMPA-approved commercial products as of early 2026:
The CAR-T Landscape in China
China has more than 250 active CAR-T clinical trials registered (more than any other country) and three NMPA-approved commercial products as of early 2026:
- Relmacabtagene autoleucel (Relma-cel, JWCAR029) — JW Therapeutics — relapsed/refractory diffuse large B-cell lymphoma
- Axicabtagene ciloleucel (Yescarta) — Fosun Kite — aggressive B-cell lymphomas
- Equecabtagene autoleucel (Eque-cel) — Innovent / IASO Bio — relapsed/refractory multiple myeloma (BCMA-targeted)
Several additional anti-CD19 and anti-BCMA constructs are in late-stage NMPA review.
The Leading Centres
Three Shanghai-based academic centres lead clinical CAR-T delivery:
- Ruijin Hospital (Shanghai Jiao Tong University) — early adopter and pioneer of academic CAR-T programs in China
- Renji Hospital — strong haematology programme, particularly multiple myeloma BCMA-CAR-T
- Beijing Boren Hospital — high-volume specialised lymphoma / myeloma CAR-T centre
West China Hospital (Chengdu) and several other academic centres run growing programmes.
The Standard Workflow
- Initial evaluation and eligibility: staging, biopsy review, PET/CT, cardiac evaluation, performance status — typically 1 week
- Apheresis: T-cell collection, typically a single 3–5 hour session
- Manufacturing window: 14–21 days for ex vivo CAR-T construct production
- Lymphodepletion chemotherapy: typically fludarabine + cyclophosphamide × 3 days
- CAR-T infusion: single outpatient or short inpatient session
- Inpatient monitoring (CRS / ICANS): typically 2–3 weeks in dedicated unit
- Post-discharge follow-up: 30-day, 60-day, 100-day, 6-month, 12-month with response imaging
Outcomes
Published Phase II data and real-world experience from Chinese centres show response rates broadly comparable to US/EU CAR-T outcomes for matched indications. For relapsed/refractory DLBCL, complete response rates of 50–60% are typical at major academic centres, with 12-month progression-free survival around 35–45%.
Cytokine release syndrome (CRS) rates and severity are managed with established protocols (tocilizumab, corticosteroids). Class A centres have dedicated CRS / ICANS protocols and intensive care backup.
Cost and Logistics for International Patients
CAR-T pricing for international patients at academic centres varies significantly by product. For NMPA-approved commercial products, the all-in price (manufacturing + admission + monitoring + follow-up) is typically USD 200,000–350,000, vs USD 475,000+ list for axicabtagene ciloleucel in the US (plus admission, ICU, monitoring extras that frequently add USD 100,000+).
Trial-based access (academic protocols) at major centres can be substantially lower cost.
The Time Investment
Plan for 8–12 weeks total in country: 1–2 weeks evaluation, 3 weeks manufacturing window, 3–4 weeks infusion + inpatient monitoring, 1–2 weeks for early follow-up. Long-term follow-up can be coordinated via telehealth and home-country oncology continuity.
Who Should Consider This?
This is for patients with relapsed/refractory disease in approved indications who have exhausted standard-of-care or can't access CAR-T affordably elsewhere. The remote second opinion pathway is the appropriate first step. See our remote second opinion page.
Sources: NMPA CAR-T approval registry; published Chinese Phase II outcomes data; Ruijin and Renji haematology programme reports; partner-network CAR-T pricing data 2026.